Upcoming KOL Webinar by scPharmaceuticals
scPharmaceuticals Inc. (NASDAQ: SCPH), a company dedicated to innovating and enhancing the administration of infused therapies, is excited to announce their upcoming Key Opinion Leader (KOL) webinar. The event promises to deliver valuable insights, particularly focusing on their flagship product, FUROSCIX, which plays a significant role in treating fluid overload, especially in patients suffering from heart failure.
Webinar Focus: Expert Insights
The KOL webinar will feature Dr. Michael Aaronson, MD, a respected nephrologist with over two decades of experience. He will provide an expert perspective on using FUROSCIX for managing fluid overload not just in heart failure patients but also for those dealing with chronic kidney disease (CKD). This session aims to highlight the efficacy and innovative delivery of FUROSCIX in these complex clinical scenarios.
Details of the Webinar
The KOL webinar is scheduled for a future date, with exact timings yet to be confirmed. Attendees will gain a unique opportunity to interact with Dr. Aaronson, who will present important findings and emerging trends in nephrology relevant to FUROSCIX. A live Q&A session will follow Dr. Aaronson's presentation, allowing for engaging discussions and clarifications on usage, safety, and effectiveness.
About FUROSCIX
FUROSCIX (furosemide injection) is specifically indicated for treating congestion due to fluid overload in adult patients with chronic heart failure. This product represents a significant advancement in therapeutic options, with its subcutaneous administration allowing patients greater flexibility and ease of use in outpatient settings.
Regulatory Update
In an exciting development, the FDA has assigned a PDUFA target action date to scPharmaceuticals to consider the Supplemental New Drug Application (sNDA) for FUROSCIX, which seeks to broaden its indications to include treatment options for fluid overload in CKD. This potential expansion could greatly enhance treatment options for patients and healthcare providers alike.
Corporate Vision
scPharmaceuticals is committed to continuing its growth and innovation. The management team periodically provides corporate updates on the company's progress, emphasizing milestones such as the recent approval expansion of FUROSCIX for patients with New York Heart Association (NYHA) Class IV heart failure. Both short and long-term strategic goals remain focused on enhancing patient care and reducing overall healthcare costs.
Contact Information
For more details about the webinar or to learn more about scPharmaceuticals' innovative therapies, potential attendees can reach out to Katherine Miranda at 781-301-6869 or via email. Investors can contact PJ Kelleher from LifeSci Advisors for further inquiries.
Frequently Asked Questions
What is the focus of the KOL webinar by scPharmaceuticals?
The webinar will focus on Dr. Michael Aaronson's insights into using FUROSCIX for treating fluid overload in heart failure and chronic kidney disease.
When is the KOL webinar scheduled?
The specific date is yet to be confirmed, but it will occur in the near future.
Who will be presenting in the webinar?
Dr. Michael Aaronson, MD, a noted nephrologist, will be the keynote speaker.
What is FUROSCIX?
FUROSCIX is a furosemide injection indicated for the treatment of fluid overload in adult patients with chronic heart failure.
How can I contact scPharmaceuticals for more details?
You can contact Katherine Miranda at 781-301-6869 for further information.
